Overview
The food supplement Endocalyx is considered to support the endothelial glycocalyx integrity by supplying sulfated polysaccharides, anti-oxidant enzymes and additional substrates for glycocalyx synthesis. The investigators will study the effect of Endocalyx on endothelial, vascular and left ventricular myocardial function in patients with COVID-19 infection.
Description
Sixty patients who have been hospitalized due to COVID-19 infection will be randomized to receive food supplement Endocalyx (4 capsules per day) (n=30) or placebo (n=30) for 4 consecutive months.
Eligibility
Inclusion Criteria:
- caucasian patients
- hospitalization for COVID-19 infection
- diagnosis of COVID-19 proven by PCR
Exclusion Criteria:
- Pregnancy and breastfeeding
- Foreseen inability to attend scheduled visits
- History of acute coronary syndrome. Coronary artery disease will be excluded by a clinical history, examination and electrocardiogram.
- Moderate or severe valve disease
- Primary cardiomyopathies
- Chronic obstructive pulmonary disease
- Asthma
- Chronic kidney disease (estimated glomerular filtration rate [eGFR] ≤60 ml/min/1.73 m2)
- Liver failure
- Malignancies